March 12, 2026

Moving into a New Era of Cryosafety

Mesenchymal stem cells (MSCs) are multipotent, meaning they can differentiate into various types of specialised cells. They primarily form connective tissues within the musculoskeletal system, including cartilage (chondrocytes), bone (osteocytes), muscle (myocytes) and fat (adipocytes).
January 29, 2025

Revolutionising cryogenic storage: How the latest advancements can benefit you

Cryogenic sample storage technology has evolved significantly to meet the growing demands of customers, especially in industries like biopharma, where stringent regulatory compliance and operational efficiency are paramount. The transition from small aluminium vessels to large stainless-steel ones reflects the increasing need for high-capacity, efficient vapour-phase storage that can safeguard valuable biological materials.
May 14, 2024

Biopharma Group is pleased to announce that IC Biomedical has designated us as its Premier Service Provider for their full range of cryogenic storage vessels across the UK and Ireland

Under the new partnership agreement, Biopharma Group assumes exclusive responsibility as technical service provider across the UK & Ireland, supporting IC Biomedical's full range of cryogenic storage solutions. This is in addition to the existing agreement covering the sales of the TW (IC Biomedical) range of cryogenic stainless steel storage vessels.
December 20, 2023

The Transformative Power of Automation in Modern Biobanking Laboratories

In the evolving landscape of Biobanking and cell banking, the integration of automation can be a transformative force, revolutionising the way laboratories store, manage and make use of cryogenically preserved cells and tissues. As the demand for precision, efficiency and scalability continues to rise, automation stands at the forefront, offering many benefits to modern biobanking laboratories.
November 10, 2023

The role of Cryopreservation within Cell and Gene Therapy

Cell and gene therapies are innovative approaches to treating diseases by harnessing the power of a patient's own cells or by introducing genetic material to correct or modify cellular functions. These therapies have the potential to revolutionise the field of medicine and provide new treatment options for a wide range of diseases, including genetic disorders, cancer, cardiovascular diseases, neurodegenerative disorders and autoimmune diseases.